• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma

By: Exicure, Inc. via Business Wire
April 14, 2025 at 18:11 PM EDT

Exicure, Inc. (Nasdaq: XCUR) today announced that GPCR Therapeutics USA, a subsidiary of Exicure Inc., has dosed the 19th patient in its ongoing Phase 2 clinical trial evaluating GPC-100 (burixafor), a small molecule CXCR4 inhibitor, for the mobilization of stem cells in multiple myeloma (MM) patients undergoing autologous stem cell transplant (ASCT) (NCT05561751).

The study is an open-label, multi-center trial evaluating the safety and efficacy of GPC-100 and propranolol in combination with G-CSF. Data from an interim analysis of 10 patients were previously presented at the 2024 American Society of Hematology (ASH) Annual Meeting.

Preliminary results are encouraging, with 100% of patients achieving the primary endpoint of successful CD34+ stem cell mobilization, including patients previously treated with daratumumab. Notably, GPC-100 enabled same-day administration of the mobilizing agent and leukapheresis, offering faster kinetics compared to FDA-approved agents such as plerixafor and motixafortide, which require overnight pre-treatment. Median times to neutrophil and platelet engraftment were 11 and 14 days, respectively, which is consistent with standard of care.

This trial is expected to finish patient recruitment at the end of April.

About Exicure, Inc.

Exicure, Inc. has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. Following its restructuring and suspension of clinical and development activities, the Company is exploring strategic alternatives to maximize stockholder value. For further information, see www.exicuretx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250414193932/en/

Contacts

Media Contact:

Sarah Ellinwood, PhD

Kendall Investor Relations

sellinwood@kendallir.com

More News

View More
Johnson & Johnson's M&A Strategy Is the Real Story for Investors
Today 12:04 EDT
Via MarketBeat
Tickers JNJ KVUE PTGX
Tesla: Some Analysts Are Calling for A 30% Drop—Time to Panic?
Today 9:36 EDT
Via MarketBeat
Topics Artificial Intelligence
Tickers TSLA
Hedge Funds Flip on the Dollar—A Buy Signal for These 3 Stocks?
Today 8:35 EDT
Via MarketBeat
Topics Bonds Stocks World Trade
Tickers ABNB DAL DOW HD
Happy Third Birthday to the Bull Market
Today 8:22 EDT
Via MarketBeat
Topics Artificial Intelligence Stocks
Tickers NVDA PLTR TSLA
MarketBeat Week in Review – 10/13 - 10/17
Today 7:00 EDT
Via MarketBeat
Topics Artificial Intelligence Economy World Trade
Tickers ACHR AMZN APLD APP ASTS CRM

Recent Quotes

View More
Symbol Price Change (%)
AMZN  213.04
-1.43 (-0.67%)
AAPL  252.29
+4.84 (1.96%)
AMD  233.08
-1.48 (-0.63%)
BAC  51.28
+0.84 (1.67%)
GOOG  253.79
+1.91 (0.76%)
META  716.91
+4.84 (0.68%)
MSFT  513.58
+1.97 (0.39%)
NVDA  183.16
+1.35 (0.74%)
ORCL  291.31
-21.69 (-6.93%)
TSLA  439.31
+10.56 (2.46%)
FinancialContent
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap